Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molgramostim

Next Previous
Drug Profile

Molgramostim

Alternative Names: CSF 39300; GM-CSF; GMC 89107; Leucomax; SCH 39300

Latest Information Update: 18 Nov 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Class Antibacterials; Antibronchitics; Antifibrotics; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors; Recombinant proteins
  • Mechanism of Action Granulocyte macrophage colony stimulating factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Agranulocytosis

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 29 Jan 2003 Genetics Institute is now called Wyeth
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top